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Summary
Fat tissue, frequently the largest organ in humans, is at
the nexus of mechanisms involved in longevity and
age-related metabolic dysfunction. Fat distribution and
function change dramatically throughout life. Obesity is
associated with accelerated onset of diseases common in
old age, while fat ablation and certain mutations affect-
ing fat increase life span. Fat cells turn over throughout
the life span. Fat cell progenitors, preadipocytes, are
abundant, closely related to macrophages, and dysdiffer-
entiate in old age, switching into a pro-inflammatory,
tissue-remodeling, senescent-like state. Other mesenchy-
mal progenitors also can acquire a pro-inflammatory,
adipocyte-like phenotype with aging. We propose a
hypothetical model in which cellular stress and preadipo-
cyte overutilization with aging induce cellular senes-
cence, leading to impaired adipogenesis, failure to
sequester lipotoxic fatty acids, inflammatory cytokine
and chemokine generation, and innate and adaptive
immune response activation. These pro-inflammatory
processes may amplify each other and have systemic con-
sequences. This model is consistent with recent concepts
about cellular senescence as a stress-responsive, adaptive
phenotype that develops through multiple stages, includ-
ing major metabolic and secretory readjustments, which
can spread from cell to cell and can occur at any point dur-
ing life. Senescence could be an alternative cell fate that
develops in response to injury or metabolic dysfunction
and might occur in nondividing as well as dividing cells.
Consistent with this, a senescent-like state can develop in
preadipocytes and fat cells from young obese individuals.
Senescent, pro-inflammatory cells in fat could have pro-
found clinical consequences because of the large size of
the fat organ and its central metabolic role.
Key words: aging; cellular senescence; diabetes; fat
tissue; inflammation; obesity; preadipocyte.
Introduction
Fat tissue is at the nexus of mechanisms and pathways involved
in longevity, genesis of age-related diseases, inflammation, and
metabolic dysfunction. Major changes in fat distribution and
function occur throughout life. In old age, these changes are
associated with diabetes, hypertension, cancers, cognitive dys-
function, and atherosclerosis leading to heart attacks and
strokes (Guo et al., 1999; Lutz et al., 2008). Excess or dysfunc-
tional fat tissue appears to accelerate onset of multiple age-
related diseases, while interventions that delay or limit fat tissue
turnover, redistribution, or dysfunction in experimental animals
are associated with enhanced healthspan and maximum life
span. For example, obesity leads to reduced life span and clinical
consequences similar to those common in aging (Ahima, 2009).
Conversely, life span is extended: (i) by caloric restriction [which
preferentially leads to reduced visceral fat (Barzilai & Gupta,
1999; Masoro, 2006)]; (ii) in fat cell insulin receptor (FIRKO),
insulin receptor substrate-1 (IRS-1), and S6 kinase-1 knockout
mice [each of which has limited fat development (Bluher et al.,
2003; Um et al., 2004; Selman et al., 2008, 2009)]; (iii) in
growth hormone receptor knockout (GHRKO) mice [which have
reduced IGF-1, delayed increase in the ratio of visceral to subcu-
taneous fat, and most likely reduced fat cell progenitor turnover
(Berryman et al., 2008)]; (iv) with rapamycin treatment [which
limits fat tissue development (Chang et al., 2009; Harrison
et al., 2009)]; and (v) after surgical removal of visceral fat (Muz-
umdar et al., 2008). One reason why age-related changes in fat
tissue function may entail such profound systemic consequences
is that fat is frequently the largest organ in humans. Indeed, it
constitutes over half the body in an alarmingly high and increas-
ing number of people [e.g., in women, who have a higher per-
cent body fat than men, with a body mass index (BMI) over
35 kg m)2].
Exciting new data are beginning to point to the cell biological
and molecular mechanisms that determine how aging impacts
fat tissue function and how this, in turn, leads to age-related dis-
ease. Lessons from what happens in obesity are especially illumi-
nating. In particular, inflammatory processes linked to cellular
senescence in fat tissue could be pivotal. Fat tissue is important
in host defense, immunity, injury responses, and production of
inflammatory cytokines and chemokines. It is rich in progenitors
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that can produce pro-inflammatory factors and that are suscep-
tible to cellular senescence. We suggest the possibility that
cellular injury responses, activation of innate immunity, accumu-
lation of dysfunctional, dysdifferentiated progenitors [mesen-
chymal macrophage- and adipocyte-like default (MAD) cells
(Kirkland et al., 2002)], and cellular senescence may all be
within a spectrum of activated pro-inflammatory fates compris-
ing an alternative differentiation state. Accumulation of senes-
cent cells in fat with aging could be caused by increased
generation of these cells owing to a combination of replicative,
cytokine-induced, and metabolic stresses as well as reduced
removal of senescent cells because of failure of immune cells
from older individuals to respond efficiently to chemokines
released by senescent cells. In cancer, these chemokines cause
the immune system to hone in on senescent cells and the cancer
cells around them, resulting in destruction of the cancer cells
and removal of the senescent cells (Xue et al., 2007). Further-
more, there are indications that a senescent-like state can occur
in nonreplicating, differentiated cells in fat tissue. If true, these
points would challenge existing concepts about cellular senes-
cence. To begin to address these hypotheses, relevant findings
about aging, obesity, cellular senescence, and inflammation in
fat tissue will be considered.
Fat tissue
Fat tissue function
In addition to storing energy, fat is important in immune and
endocrine function, thermoregulation, mechanical protection,
and tissue regeneration. The main role of fat is to store calori-
cally dense fatty acids. These highly reactive, cytotoxic molecules
are sequestered as less reactive triglyceride within fat droplets,
protecting against systemic lipotoxicity [cytotoxicity owing to
fatty acids and lipid metabolites; (Tchkonia et al., 2006a)]. To
accommodate wide swings in nutrient availability, fat tissue is
capable of rapid, extensive changes in size, especially subcuta-
neous fat, which is not subject to the anatomic constraints to
growth that limit visceral fat. Growth is accomplished through
changes in fat cell size or number that vary in magnitude among
fat depots.
Adipose tissue is located strategically beneath the skin and
around vital organs, where it protects against infection and
trauma. Bacterial and fungal infections of fat are uncommon,
and metastases are unusual, likely related to the innate and
adaptive immune elements in fat tissue, as well as potentially
high local fatty acid concentrations that are lethal to pathogens
and nonadipose cell types (Tchkonia et al., 2006a). Dysregulat-
ed activation of fat tissue immune responses may predispose
individuals to the metabolic dysfunction common in both obes-
ity and aging.
Fat tissue produces hormones, including IL-6, angiotensin II,
leptin, adiponectin, and IGF-1 (in response to GH), and activates
hormones, for example glucocorticoids and sex steroids. It
releases paracrine factors in an endocrine-like fashion by devel-
oping in target organs and releasing factors that impact their
function. For example, fat in muscle regulates muscle glucose
homeostasis and insulin responses (Abel et al., 2001). In addi-
tion to regional variation in fat tissue endocrine and paracrine
factor production, differences in venous drainage contribute to
the distinct metabolic effects of different fat depots. For exam-
ple, omental and some regions of mesenteric fat drains directly
into the liver through the portal vein.
Adipose tissue is involved in thermoregulation, both by pre-
venting heat loss through its insulating effects and by generat-
ing heat in brown fat. Fat affords mechanical protection by
developing at sites of mechanical stress or pressure. It forms a
buffer that dissipates pressure over bony prominences, prevent-
ing skin breakdown. Fat is rich in mesenchymal progenitors that
can give rise to multiple cell types, including fat cells (Cartwright
et al., 2007). The multipotent progenitors resident in fat may
promote tissue regeneration during wound healing.
Aging
Fat tissue mass increases through middle age and declines in old
age (Visser et al., 2003; Raguso et al., 2006). Fat is redistributed
among different fat depots over time, especially during and after
middle age, when fat redistributes from subcutaneous to intra-
abdominal visceral depots (Meunier et al., 1971; Kotani et al.,
1994; Matsuzawa et al., 1995; Kyle et al., 2001; Raguso et al.,
2006; Slawik & Vidal-Puig, 2006; Cartwright et al., 2007; Rab-
kin, 2007; Kuk et al., 2009). Consistent with this, the percent of
meal fat stored in subcutaneous depots is lower in older than
younger men and women, and abdominal circumference
increases by 4.0 cm every 9 years in adult women (Hughes
et al., 2004; Koutsari et al., 2009). In old age, fat is redistributed
outside fat depots, accumulating in bone marrow, muscle, liver,
and other ectopic sites. As in aging, genetic and acquired lipody-
strophic syndromes are associated with fat tissue dysfunction,
subcutaneous fat loss, increased visceral and ectopic fat, and
metabolic syndrome [glucose intolerance, insulin resistance,
central obesity, dyslipidemia, and hypertension (Garg & Agar-
wal, 2009)]. Metabolic syndrome in the elderly, in turn, is associ-
ated with increased inflammation, cardiovascular and all-cause
mortality, cognitive impairment, and accelerated functional
decline (Koster et al. 2010; Morley, 2004).
As in humans, mice and rats have fat redistribution and ecto-
pic fat deposition with aging. This is delayed in mouse models
with increased maximum life span because of growth hormone
and ⁄ or insulin-like growth factor-1 (IGF-1) deficiency. While
short-term growth hormone exposure decreases visceral fat by
enhancing lipolysis, in animals with lifelong excess growth hor-
mone, fat redistribution begins earlier, advances faster, and is
associated with decreased life span (Berryman et al., 2004,
2009; Palmer et al., 2009). Removal of visceral fat enhances
insulin sensitivity and extends maximum life span in rats (Barzilai
et al., 1999; Muzumdar et al., 2008; Huffman & Barzilai, 2009).
Conversely, decreased ability of subcutaneous adipocytes to
store lipid, as occurs with aging, may contribute to metabolic
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complications by causing systemic lipotoxicity (Lelliott & Vidal-
Puig, 2004; Carley & Severson, 2005; Unger, 2005; Uranga
et al., 2005; Tchkonia et al., 2006a; Kuk et al., 2009). Thus, fat
redistribution with aging occurs across species and is associated
with age-related diseases, lipotoxicity, and reduced longevity,
while retention of a high ratio of functioning subcutaneous to
visceral fat is associated with enhanced longevity.
Substantial changes in fat tissue metabolic function occur dur-
ing aging, with declines in insulin, lipolytic, and fatty acid
responsiveness (Bertrand et al., 1980; Yu et al., 1982; Kirkland
& Dax, 1984; Yki-Jarvinen et al., 1986; Silver et al., 1993; Gre-
german, 1994; Kirkland & Dobson, 1997; Kirkland et al., 2002;
Das et al., 2004; Tchkonia et al., 2006a). Together with prea-
dipocyte dysfunction, impairments in ability to accumulate or
mobilize lipid with aging reduce the dynamic range over which
fat cells can store or release energy or respond to excess
systemic lipotoxic fatty acids.
Fat tissue cytokines, including tumor necrosis factor-a (TNFa)
and interleukin (IL-6), can increase with aging (Morin et al.,
1997; Starr et al., 2009). Increased adiponectin, a cytokine that
exists in several isoforms and that originates from fat as well as
other tissues, has been associated with reduced risk of metabolic
syndrome in the elderly (Lim et al. 2010; Stenholm et al., 2009).
It is higher in centenarians and their offspring than the general
population (Atzmon et al., 2008). However, increased adipo-
nectin is associated with increased mortality in the elderly,
perhaps related to production by the vascular system in athero-
sclerosis (Rizza et al. 2010; Poehls et al., 2009). More needs to
be done to understand whether there are age-related changes
in adiponectin production by cells in fat tissue and what the
consequences are.
Immune effector abundance appears to change with aging in
a fat depot-dependent manner. Macrophage abundance
increases in subcutaneous fat with aging in mice (Jerschow
et al., 2007). However, macrophage numbers that are already
high in intra-abdominal fat of young mice do not increase fur-
ther with aging (Harris et al., 1999; Jerschow et al., 2007). Little
is known about the impact of aging on fat tissue lymphocyte,
mast cell, or macrophage abundance in humans.
Brown fat generates heat through uncoupled mitochondrial
oxidative phosphorylation. Aging is associated with loss of
brown fat as well as brown fat preadipocyte dysfunction in
rodents (Gabaldon et al., 1998; McDonald & Horwitz, 1999;
Gabaldon et al., 2003). This is delayed by caloric restriction
(Valle et al., 2008). Brown fat also decreases with aging in
humans, in whom it is interspersed with white fat in the neck
and upper chest (Cypess et al., 2009). Decreased brown fat may
contribute to thermal dysregulation and energy imbalance.
Obesity
Obesity has been likened to an accelerated form of fat tissue
aging (Ahima, 2009; Minamino et al., 2009; Tchkonia et al.,
2009). Obesity causes premature death from many of the same
causes as those common in elderly lean individuals: diabetes,
heart attacks, strokes, cancer, and dementia (Bjorntorp, 1990;
Denke et al., 1993, 1994; Colditz et al., 1995; Lean, 2000).
Obesity and aging are both associated with chronic, low-grade
inflammation and insulin resistance, increased local and circulat-
ing proinflammatory, chemotactic, and procoagulant proteins,
and ectopic lipid deposition with lipotoxicity (Hotamisligil &
Spiegelman, 1994; Samad et al., 1996, 1997; Vgontzas et al.,
1997; Fried et al., 1998; Loffreda et al., 1998; Samad et al.,
1998; Ferri et al., 1999; Visser et al., 1999; Perreault & Marette,
2001; De Pergola & Pannacciulli, 2002; Weyer et al., 2002;
Sartipy & Loskutoff, 2003; Takahashi et al., 2003; Weisberg
et al., 2003; Xu et al., 2003; Curat et al., 2004; Tchkonia et al.,
2006a). This is especially true in massive or visceral obesity. As in
aging, fat tissue adipogenic transcription factor expression is
decreased in obesity, and inflammatory mediators, including
TNFa and IL-6, are increased (Nadler et al., 2000; Xu et al.,
2002; Weisberg et al., 2003; Xu et al., 2003; Nair et al., 2005;
Jerschow et al., 2007). Much more is known about fat tissue
dysfunction in obesity than aging. Analysis of processes causing
fat tissue dysfunction in obesity could point to mechanisms
contributing to metabolic dysfunction with aging and even the
aging process itself.
Events leading to fat tissue inflammation in obesity have been
investigated by examining effects of high fat feeding in rodents
(Fig. 1). These diets induce fat tissue inflammatory cytokine,
chemokine, and extracellular matrix (ECM)-modifying protein
production within days to weeks (Xu et al., 2003; Suganami
et al., 2005; Nishimura et al., 2009). This is associated with
shifts in T-lymphocyte subsets, rather than absolute numbers of
T lymphocytes (Feuerer et al., 2009; Nishimura et al., 2009).
High fat feeding results in an increased proportion of CD8+
effector T lymphocytes, with a progressive increase in cells
releasing pro-inflammatory TH1 cytokines, relative to CD4
+
helper cells and T regulatory cells [Tregs; (Feuerer et al., 2009;
Nishimura et al., 2009; Winer et al., 2009)]. This also occurs in
humans: CD8A is higher and Tregs are reduced in fat tissue from
obese compared to lean humans (Feuerer et al., 2009; Nishim-
ura et al., 2009). Fat tissue from obese mice induces CD8+ lym-
phocyte activation and proliferation in coculture (Nishimura
et al., 2009), suggesting chemokines produced by fat could be
upstream of changes in T-lymphocyte subsets. Fat also becomes
infiltrated by mast cells as obesity develops in mice and humans
(Liu et al., 2009). Mast cells contribute to production of IL-6,
interferon-c, and metabolic complications of obesity, including
insulin resistance and fatty liver.
Following shifts in T-lymphocyte subsets and mast cell accu-
mulation during development of obesity, fat becomes infiltrated
by classically activated M1 macrophages (Weisberg et al., 2003;
Xu et al., 2003; Kintscher et al., 2008; Liu et al., 2009; Lumeng
et al., 2009; Nishimura et al., 2009). This is likely due to chemo-
kines, including interferon-c [from T lymphocytes, and mast cells
(Kintscher et al., 2008; Liu et al., 2009; Sebastian et al., 2009;
Winer et al., 2009)], monocyte chemoattractant protein-1
[MCP-1; from preadipocytes and other cell types (Gustafson
et al., 2009)], RANTES [from preadipocytes, endothelial cells,
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and other cell types (Feuerer et al., 2009)], and RARRES2 [from
preadipocytes (Kralisch et al., 2009)]. Little MCP-1 or RANTES is
produced by fat cells themselves (Fain et al. 2009).
The stromal vascular fraction of adipose tissue (comprising
preadipocytes, endothelial cells, immune cells, and other cell
types) may be the main source of inflammatory cytokines and
chemokines produced by fat (Fain et al. 2009; Wu et al., 2007;
Gustafson et al., 2009). Macrophage infiltration owing to a high
fat diet depends more on cells in the stromal vascular fraction of
fat tissue than fat cells (Weisberg et al., 2003). Once activated,
macrophages release yet more inflammatory cytokines that lead
to further production of MCP-1 and other chemokines, inducing
further macrophage infiltration and inflammation in a vicious
cycle. A central question that has not been fully answered is:
what cell types, metabolites, and ⁄or antigens are upstream of
the shifts in T-lymphocyte subsets and mast cell accumulation
that precede macrophage infiltration?
Fat tissue distribution in obesity
Different fat depots make distinct contributions to the pro-
inflammatory and clinical consequences of obesity and, poten-
tially, aging. Visceral fat enlargement is more strongly associ-
ated with ectopic fat deposition, lipotoxicity, and metabolic
disease than generalized obesity, especially in old age (Carr
et al., 2004; Tchkonia et al., 2006a; Wannamethee et al.,
2007; Gustafson et al., 2009; Thomou et al., 2010). Even
otherwise lean individuals with relatively more intra- than extra-
abdominal fat are at increased risk for diabetes and mortality
(Pischon et al., 2008). Removing intra-abdominal fat reduces
insulin resistance more profoundly than removing subcutane-
ous fat from rodents (Barzilai et al., 1999; Weber et al., 2000;
Gabriely et al., 2002; Huffman & Barzilai, 2009). Removing
large amounts of subcutaneous fat from humans does not
improve insulin sensitivity (Klein et al., 2004). Subcutaneous fat
expansion in obesity may actually be protective (Kim et al.,
2007; Tran et al., 2008). Cytokine and chemokine production
by different fat depots varies, with visceral fat being more pro-
inflammatory (Samaras et al. 2010; Einstein et al., 2005; Tchko-
nia et al., 2006a; Huffman & Barzilai, 2009; Starr et al., 2009;
Thomou et al., 2010). IL-6 levels are higher in visceral than
subcutaneous fat in mice, and nutrient excess induces more
visceral fat expression of TNFa and plasminogen activator inhib-
itor-1 (PAI-1), a hemostatic factor associated with atherosclero-
sis [Einstein et al., 2005; Starr et al., 2009]).
Is obesity accelerated fat tissue aging?
While obesity is associated with accelerated development of dis-
eases common in old age, mechanisms of fat tissue dysfunction
Fig. 1 Hypothetical model of the chain of events culminating in fat tissue inflammation in obesity. Preadipocytes and fat tissue endothelial cells may acquire an
activated, pro-inflammatory, senescent-like phenotype in response to repeated replication, fatty acids, toxic metabolites, chronically high IGF-1, glucose, or other
stimuli (gray = inflamed). Inflammatory cytokines could spread this activated secretory phenotype from cell to cell and block full differentiation of preadipocytes
into insulin-responsive fat cells, amplifying the process. Chemokines, cytokines, and ECMmodifiers produced by pro-inflammatory cells might activate adaptive
immune responses. Shifts from anti- to proinflammatory T-lymphocyte subsets and mast cell infiltration owing to cytokine and lymphokine production, toxic
metabolites (including fatty acids and reactive oxygen species), and cytokines released by inflamed preadipocytes and endothelial cells may combine to promote
M1 macrophage activation. The inflammatory cytokines could induce systemic effects, further impede adipogenesis, and promote fat cell lipolysis, releasing fatty
acids that aggravate the fat tissue pro-inflammatory state and cause systemic lipotoxicity. Similar processes could be involved in age-related fat tissue
dysregulation and metabolic dysfunction. Some of these processes appear to vary in extent among fat depots in obesity (Feuerer et al., 2009;
Nishimura et al., 2009; Winer et al., 2009) as well as aging (Cartwright et al., 2010).
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in obesity differ from aging in important ways. Fat cell size is
increased in many depots in obesity (Fried & Kral, 1987) and is
associated with fat cell death and macrophage infiltration
around the dying cells (Cinti et al., 2005). In aging, unlike obes-
ity, this may not contribute substantially to inflammation,
because fat cells are generally smaller in old than middle age
(Bertrand et al., 1978, 1980). Whole fat tissue gene expression
profiles differ in obesity from changes during development
(Miard & Picard, 2008). Fat tissue transcripts that change during
development (four compared with 12 month old mice) did not
correlate well with transcripts affected by obesity (4- month-old
obese compared to lean mice). This could be related to differ-
ences between changes in fat tissue cellular composition during
development from those in obesity. For example, macrophage
infiltration in visceral fat from young obese individuals is more
impressive than lean old individuals (Weisberg et al., 2003; Xu
et al., 2003; Wu et al., 2007).
Whether the basis of fat tissue dysfunction in obesity and
aging is the same is more than academic. Clinical consequences
of obesity are increasingly close to being amenable to novel
interventions based on targeting inflammation and fat tissue cel-
lular composition. For example, antibody-mediated CD8+ deple-
tion reduces high fat diet-induced TNFa, IL-6, and M1
macrophage abundance and improves insulin responsiveness in
mice (Nishimura et al., 2009). CD3 antibody restores Tregs,
decreases pro-inflammatory M1 relative to anti-inflammatory
M2 macrophages, increases antidiabetic IL-10, and reverses
insulin resistance for over 4 months despite a high fat diet
(Winer et al., 2009). Injection of an IL-2 antibody increases Tregs
and anti-inflammatory IL10 in abdominal fat and decreases
blood glucose in mice on a high fat diet (Feuerer et al., 2009).
Transplantation of anti-inflammatory TH2 cells into lymphocyte-
deficient mice reverses insulin resistance and MCP-1 owing to a
high-fat diet (Winer et al., 2009). Reducing mast cells by genetic
manipulation or pharmacologic stabilization with disodium
chromoglycate reduces hepatic steatosis, circulating inflamma-
tory cytokines and chemokines, angiogenesis, and insulin resis-
tance in obese mice (Liu et al., 2009). Blocking TLR4 in cells
originating from bone marrow or ablating CD11c+ macrophag-
es reduces insulin resistance in obese mice (Patsouris et al.,
2008; Saberi et al., 2009). To the extent that age-related fat
tissue dysfunction is similar to obesity, analogous interventions
might prevent clinical consequences of age-related fat tissue
dysfunction.
Preadipocytes
Preadipocyte function
Preadipocytes comprise 15–50% of cells in fat, one of the larg-
est progenitor pools in the body (Fig. 2). Preadipocytes replicate
in response to mitogens, including IGF-1 (Boney et al., 2001;
Sekimoto et al., 2005). They are mainly resident in fat depots,
although a small pool of circulating fat cell progenitors exists
Fig. 2 Impact of aging, obesity, anatomic origin, and serial passage on cell dynamic mechanisms of fat tissue turnover. Up to 50% of cells in fat tissue are
committed preadipocytes that arise from multipotent, slowly replicating mesenchymal progenitor cells and possibly circulating progenitors (Hong et al., 2005;
Crossno et al., 2006). Preadipocyte numbers are maintained by replication. Preadipocytes can reversibly switch into a slowly replicating subtype, can become
macrophage-like, and may be able to progress up or down the adipocytic lineage (Cousin et al., 1999; Charriere et al., 2003; Tchkonia et al., 2005; Gustafson
et al., 2009). Preadipocytes are depleted by differentiation into fat cells, apoptosis, necrosis, and cellular senescence. Enlargement of fat cells (lipid accumulation)
and maintenance of insulin responsiveness are tied to processes initiated during differentiation, including adipogenic transcription factor expression. Fat cells,
especially large fat cells, can be removed by a process with features of both apoptosis and necrosis and that can induce inflammation. The balance among these
cell dynamic properties determines preadipocyte and fat cell numbers. Cell dynamic processes that vary with aging are in bold, obesity are underlined, anatomic
origin in Italics, and serial passage in parentheses. These differences persist for at least 40 population doublings in cloned preadipocytes in the case of anatomic
origin, 16 in aging, and 8 in obesity.
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(Crossno et al., 2006). Preadipocytes, in turn, may arise from or
be the same as the multipotent mesenchymal progenitors (also
referred to as adipose tissue stem cells) that tend to be aligned
along fat tissue blood vessels in a pericyte-like fashion (Tang
et al., 2008). Preadipocytes resident in different fat depots are
distinct cell subtypes that differ in developmental gene expres-
sion and capacities for replication, differentiation, and apoptosis
(Yamamoto et al. 2010; Kirkland et al., 1990; Tchkonia et al.,
2001, 2002, 2006b, 2007b). These differences persist for at
least 40 population doublings in strains made by expressing telo-
merase in single human preadipocytes from different fat depots.
Regional differences in preadipocyte clonal capacities for repli-
cation and adipogenesis predict subsequent fat tissue growth
(Wang et al., 1989).
Preadipocyte metabolic and secretory profiles are distinct from
differentiated fat cells and vary among fat depots (Kirkland
et al., 1994, 2003; Tchkonia et al., 2007b). Preadipocytes
express toll-like receptors and have full innate immune response
capability (Lin et al., 2000; Chung et al., 2006; Vitseva et al.,
2008). Preadipocytes with activated immune responses likely
make a larger contribution than macrophages to age-related fat
tissue dysfunction because of their numbers (Xu et al., 2002;
Gustafson et al., 2009; Mack et al., 2009). Gene expression
profiles of preadipocytes are closer to macrophages than fat
cells (Charriere et al., 2003). TNFa and hypoxia induce preadipo-
cytes to release cytokines and chemokines that activate endo-
thelial cells and promote macrophage infiltration (Mack et al.,
2009). Treatment of undifferentiated human preadipocytes with
TNFa or lipopolysaccharide (LPS) induces CD68, MIP1a, IL-1b,
and GM-CSF expression (Gustafson et al., 2009). Activated
preadipocytes can even acquire a macrophage-like morpho-
logical phenotype (Cousin et al., 1999; Gustafson et al., 2009).
Their plasticity and capacity to mount innate immune responses
enable preadipocytes to participate in wound repair and defense
against infection but also predispose them to contribute to fat
tissue inflammation and dysfunction.
The main role of preadipocytes is to give rise to new fat
cells. Following initiation of differentiation through signaling
pathways activated by fatty acids, IGF-1, glucocorticoids, and
other stimuli, a cascade of transcription factors underlies
acquisition and maintenance of the fat cell phenotype (Low-
ell, 1999; Rosen, 2005). The key ‘bottleneck’ in this process
is at the level of the adipogenic transcription factors, peroxi-
some proliferator-activated receptor-c (PPARc) and CCAA-
T ⁄ enhancer binding protein-a [C ⁄ EBPa; (Lin & Lane, 1994;
Hu et al., 1995; Wu et al., 1995; Yeh et al., 1995; Wu et al.,
1999; Farmer, 2005)]. PPARc binds a ligand [e.g., endoge-
nous or dietary lipids or thiazolidinedione (TZD) antidiabetic
drugs], heterodimerizes with a ligand-bound retinoid receptor
and then induces C ⁄ EBPa (Wu et al., 1996; Hamm et al.,
2001). C ⁄ EBPa, in turn, further increases PPARc expression
(Clarke et al., 1997; Burgess-Beusse et al., 1999). C ⁄ EBPa
and PPARc cooperate in regulating downstream adipogenic
genes (Hollenberg et al., 1997; El Jack et al., 1999). Sus-
tained activity of both is necessary for development of fully
functional, insulin-responsive fat cells and for downregulating
the pro-inflammatory proclivities of preadipocytes.
Aging and preadipocyte function
Extensive changes in preadipocyte function occur with aging
[Fig. 2; (Djian et al., 1983; Wang et al., 1989; Kirkland et al.,
1990, 1993, 1994, 1997; Kirkland & Dobson, 1997; Kirkland &
Hollenberg, 1998; Caserta et al., 2001; Karagiannides et al.,
2001; Kirkland et al., 2002; Karagiannides et al., 2006b; Guo
et al., 2007; Tchkonia et al., 2007a; Cartwright et al., 2010)].
These include declines in preadipocyte replication (Djian et al.,
1983; Kirkland et al., 1990; Kirkland & Hollenberg, 1998; Schip-
per et al., 2008), decreased adipogenesis (Kirkland et al., 1990,
1993; Karagiannides et al., 2001, 2006b), increased susceptibil-
ity to lipotoxicity (Guo et al., 2007), and increased pro-inflam-
matory cytokine, chemokine, ECM-modifying protease, and
stress response element expression (Tchkonia et al., 2007a;
Cartwright et al., 2010). These changes progress at different
rates and to different extents in preadipocytes from different fat
depots (Djian et al., 1983; Kirkland et al., 1990; Schipper et al.,
2008; Cartwright et al., 2010). They are inherent: age-depen-
dent declines in replication and differentiation remain evident in
most clones derived from single preadipocytes cultured in paral-
lel from animals of different ages for over a month (Djian et al.,
1983; Kirkland et al., 1990). However, these changes do not
occur uniformly in every preadipocyte: occasional clones derived
from old animals replicate and accumulate lipid like the majority
of clones from young animals, and some clones from young
animals behave more like cells from old animals (Kirkland et al.,
1990).
C ⁄ EBPa, PPARc, and their target genes are lower in preadipo-
cytes cultured from older than younger humans and rats follow-
ing exposure to differentiation medium (Karagiannides et al.,
2001; Schipper et al., 2008). PPARc and C ⁄ EBPa are reduced in
fat tissue from various species in old age, including primates
(Hotta et al., 1999; Karagiannides et al., 2001). These adipo-
genic transcription factors also decline in serially passaged
human preadipocytes exposed to differentiation-inducing med-
ium, with six population doublings being sufficient to detectably
impair adipogenesis (Tchkonia et al., 2006b; Noer et al., 2009).
Human preadipocyte replicative arrest occurs after approxi-
mately 35 population doublings.
The age-related impairment in adipogenesis occurs at a point
between the early increase in C ⁄ EBPb transcription and subse-
quent increases in PPARc and C ⁄ EBPa (Karagiannides et al.,
2001). Overexpressing C ⁄ EBPa restores capacity for lipid accu-
mulation by preadipocytes from old individuals. Redundant
mechanisms impede adipogenesis at this point, including
increased expression of C ⁄ EBP homologous protein (CHOP) and
an alternatively translated, short C ⁄ EBPb isoform, C ⁄ EBPb liver-
activating protein (LIP), that lacks the full C ⁄ EBPb-transactivating
domain (Karagiannides et al., 2006b; Tchkonia et al., 2007a).
Increased binding of CUG triplet repeat-binding protein
(CUGBP) to the 5¢ region of C ⁄ EBPbmRNA with aging causes LIP
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to be translated (Karagiannides et al., 2006b). CUGBP activity,
LIP, and CHOP are cellular stress responsive and induced by
TNFa. Preadipocyte TNFa secretion, in turn, increases with aging
(Tchkonia et al., 2007a). Thus, redundant, stress responsive,
inherent processes impair adipogenesis with aging.
Decreased adipogenic transcription factors could contribute
to age-related declines in fat cell size, capacity to store lipid, and
insulin responsiveness [both PPARc and C ⁄ EBPa are required for
fat cells to be insulin–responsive; (El Jack et al., 1999)]. These
changes occur at different rates in different depots, with
subcutaneous depots being particularly affected, potentially
contributing to fat redistribution, lipodystrophy, ectopic lipid
accumulation, lipotoxicity, and metabolic dysfunction. Even
preadipocytes become susceptible to lipotoxicity because of
fatty acids in old age, related to reduced expression of adipo-
genic transcription factors and enzymes required for processing
fatty acids into triglycerides (Guo et al., 2007). Fatty acids also
induce fat tissue cytokine release (Suganami et al., 2005),
further impeding adipogenesis, leading to a downward spiral.
While influences extrinsic to fat tissue, including systemic dis-
ease and changes in diet, activity, and hormones, likely contrib-
ute to fat dysfunction in old age, inherent, age-related changes
in preadipocytes set the stage for fat tissue and systemic meta-
bolic dysfunction.
Reduced PPARc in mouse models is associated with lipodys-
trophy and reduced life span (Argmann et al., 2009). An
increase in maximum life span owing to manipulating PPARc
would need to be demonstrated before concluding definitively
that it is involved in progression of aging. On the other hand,
gene knock-in replacement of C ⁄ EBPa with C ⁄ EBPb results in
increased mean and maximum life span together with leanness,
resistance to diet-induced obesity, and increased energy expen-
diture (Chiu et al., 2004). Thus, age-related changes in prea-
dipocyte and fat cell adipogenic transcription factors may
contribute not only to morbidity, manipulating them may also
prove to delay age-related dysfunction.
MAD cells
Generation of MAD cells potentially contributes to ectopic lipid
accumulation in old age (Kirkland et al., 2002). Preadipocytes
are closely related to other mesenchymal progenitors, including
osteoblasts, muscle satellite cells, chondroblasts, and macro-
phages. In old age, muscle satellite cells, osteoblasts, and macro-
phages can sometimes dysdifferentiate into cells with an
incomplete, adipocyte-like phenotype, with lipid accumulation
and expression of the fat cell-specific fatty acid-binding protein,
aP2, and PPARc (but insufficient PPARc for differentiation into
fully functional, insulin-responsive fat cells). Failure to express
sufficient levels of the transcription factors that direct uncom-
mitted mesenchymal cells into becoming fully functional, spe-
cialized cells may contribute to their developing into partially
differentiated adipocyte-like cells by default. In muscle, satellite
cells from old mice acquire a partial adipocyte phenotype with
more lipid accumulation and aP2, C ⁄ EBPa, and PPARc expres-
sion than cells from young mice (Taylor-Jones et al., 2002). In
bone, osteoblast formation from mesenchymal progenitors is
decreased with aging, together with increased adipogenesis
(Jilka et al., 1996; Rosen et al., 2009). These changes might con-
tribute to age-related accumulation of fat in bone marrow and
muscle as well as osteoporosis.
Preadipocytes in obesity
Increased fat cell size accounts for increased fat mass in mild
obesity, while severe obesity leads to increased numbers of fat
cells and preadipocytes, together with increased fat cell turnover
because of apoptosis and ⁄ or necrosis (Shillabeer et al., 1990;
Cinti et al., 2005; Lacasa et al., 2007; Strissel et al., 2007). Pre-
adipocytes are driven to become new fat cells in massive obesity,
especially in subcutaneous fat, with preadipocyte replicative
history being increased (Cinti et al., 2005; Strissel et al., 2007;
Thomou et al., 2010). Up to 10 fold more preadipocytes can
be present in very massively obese than lean subjects (Table 1).
Additionally, preadipocyte turnover is likely increased, because
preadipocytes develop into new fat cells as fat cell number and
removal increase (Cinti et al., 2005; Strissel et al., 2007).
As in chronological aging and after serial passage in culture
(both of which are associated with increased preadipocyte repli-
cative histories), in obesity adipogenesis, C ⁄ EBPa, PPARc, and
their downstream targets are decreased in preadipocytes and
fat tissue (Turkenkopf et al., 1988; Shillabeer et al., 1990;
Permana et al., 2004; Nair et al., 2005; Dubois et al., 2006;
Tchkonia et al., 2006b; Gustafson et al., 2009). Stromal vascu-
lar cells that are aP2+ (a downstream target of C ⁄ EBPa and
PPARc) are reduced in obese women (Tchoukalova et al., 2007).
Impaired adipogenesis in obesity, associated with reduced
downregulation of preadipocyte pro-inflammatory genes and
restricted capacity to store excess fatty acid as triglyceride, may
contribute to fat tissue inflammation, ectopic lipid accumula-
tion, lipotoxicity, and insulin resistance, as occurs in aging
Table 1 Preadipocyte abundance is increased in obesity
Nonobese Obese
Height (m) 1.65 ± 0.02 1.70 ± 0.03
Weight (kg) 70 ± 6 241 ± 6
BMI (m kg)2) 25 ± 2 83 ± 2
Estimated body fat (%) 20 ± 2 58 ± 2
Fat tissue (kg) 14 ± 2 139 ± 5
Preadipocytes per g (·104) 45 ± 11 45 ± 6
Preadipocytes ⁄ subject (·109) 6.1 ± 2.2 63.1 ± 9.6
Preadipocyte numbers were determined in abdominal subcutaneous fat
from five nonobese and 15 massively obese subjects [as in (Kirkland et al.,
1994)]. Preadipocytes per g fat tissue differed little between nonobese and
obese subjects, as noted by others (van Harmelen et al., 2003). Amount of
fat tissue was increased considerably in the obese subjects, resulting in
many more preadipocytes ⁄ obese subject. The obese subjects had 31 fold
more senescent preadipocytes than nonobese subjects (95% confidence
limits 13–71), based on preadipocytes ⁄ subject and the ratio of SA b–gal+
cells in obese ⁄ lean fat tissue (=3.04). Mean ± SEM are shown.
BMI, body mass index.
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(Unger, 2002; Xu et al., 2002; Listenberger et al., 2003;
DeFronzo, 2004; Tchkonia et al., 2006a; Kim et al., 2007).
Despite low C ⁄ EBPa and PPARc, fat cell size is usually
increased in obesity. Differentiating preadipocytes with low
C ⁄ EBPa and PPARc can still accumulate lipid when exposed to
fatty acids but are insulin resistant and dysfunctional, consistent
with accretion of the large, insulin-resistant, C ⁄ EBPa- and
PPARc-deficient fat cells in obesity that are associated with dia-
betes (Xie et al., 2006; Kim et al., 2007). Restricted capacity to
increase fat cell number, with increases in fat cell size occurring
instead, is associated with lipotoxicity and elevated diabetes risk
(Dubois et al., 2006; Kim et al., 2007). Large fat cells in obesity
may have restricted capacity to take up excess fatty acid because
of: (i) low adipogenic transcription factor expression and conse-
quently impaired machinery to process fatty acids; (ii) insulin
resistance with inhibition of IRS-1 and Glut-4; (iii) increased
lipolysis with fatty acid release owing to insulin resistance;
(iv) instability from their large size, with increased risk of apopto-
sis ⁄ necrosis; and (v) high fat tissue concentrations of TNFa
[which is lipolytic and anti-adipogenic; (Cinti et al., 2005; Xie
et al., 2006; Gustafson et al., 2009)]. Fat cell dysfunction in
obesity, coupled with reduced ability of preadipocytes to differ-
entiate into fat cells, may contribute to failure to sequester fatty
acids, systemic lipotoxicity, and insulin resistance.
Fat tissue cellular senescence and
inflammation
Cellular senescence
Cellular senescence is considered to be an irreversible block to
cell cycle progression in populations of otherwise replication-
competent cells (Hayflick & Moorehead, 1961; Narita & Lowe,
2005; Beausejour & Campisi, 2007; Jeyapalan & Sedivy, 2008).
Replicative senescence in hyperproliferative states, such as can-
cer or massive obesity, may constitute a defense against morbid-
ity by removing dysfunctional or excess progenitors from
replicating pools of cells (Campisi, 2000, 2004, 2005; Xue et al.,
2007). The proportion of arrested cells in a population rises with
increasing population doublings, rather than all cells becoming
senescent at once (Martin-Ruiz et al., 2004; Passos et al., 2007).
This is reflected in vivo in particular regions in different organs in
old age, with a subset of cells, often less than 10%, expressing
p16 and other markers and effectors of senescence (Krishna-
murthy et al., 2004; Wang et al., 2009a). In addition to hyper-
proliferation, cellular senescence or stasis (Stress or Aberrant
Signaling-Induced Senescence) can be induced by stresses: telo-
mere shortening, disrupted chromatin, DNA damage, intense
mitogenic signals, oncogene activation, metabolic stress, and
stress owing to cell culture conditions (Sherr & DePinho, 2000;
Narita et al., 2003; Martin-Ruiz et al., 2004; Campisi, 2005). As
in replicative senescence, not all cells in a stressed population
undergo stasis at the same time, implying that genetic, epige-
netic, or paracrine ⁄microenvironmental conditions confer sus-
ceptibility to senescence unequally within cell populations. This
could be related to somatic drift among the individual cells in tis-
sues (Martin, 2009). Features of cellular senescence include
large, flattened cells, enlarged nucleoli, senescence-associated
b-galactosidase [SA b-gal] positivity, and other markers and
mediators of senescence, such as phospho-Ser15-p53 ⁄ p21 and
p16 ⁄ hypophosphorylated Rb pathway component expression.
Unlike p21, p16 activity appears to increase in nearly all cells as
senescence progresses (Jeyapalan & Sedivy, 2008). SA b-gal+
cells are increased in hyperproliferative diseases [e.g., cancers,
psoriasis, prostatic hypertrophy, atherosclerotic plaques; (Choi
et al., 2000; Vasile et al., 2001; Narita & Lowe, 2005; Mimura &
Joyce, 2006; Jeyapalan & Sedivy, 2008; Charalambous et al.,
2007)].
Cellular senescence takes days to weeks to become fully
established, with autocrine biochemical loops involving reactive
oxygen species (ROS), IL-6, transforming growth factor-b, and
other signals eventually resulting in focal accumulation of
heterochromatin (Passos et al. 2010; Kuilman et al., 2008;
Kuilman & Peeper, 2009; Passos et al., 2009). These heterochro-
matic foci can be identified by 4¢,6-diamidino-2-phenylindole
(DAPI) staining and by the activated histones that contribute to
DNA repair and stabilization, including c-phosphorylated his-
tone-2AX [cH2AX; (Wang et al., 2009a)]. In human replicative
senescence, heterochromatic foci can be associated with telo-
meres (telomere-induced foci).
Cellular senescence leads to a senescent secretory phenotype
with increased inflammatory cytokines, altered production of
ECM-modifying proteases, and production of ROS (Freund
et al.; Passos et al. 2010; Krtolica & Campisi, 2002; Parrinello
et al., 2005; Xue et al., 2007; Coppe´ et al., 2008). Generation
of cytokines, chemokines, and ECM modifiers by senescent cells
leads to death of cells around them, tissue remodeling, and
attraction of immune elements. Although senescent cells are
often resistant to apoptosis (Campisi, 2003), activation of the
immune system by senescent cells causes removal of nearby cells
as well as the senescent cells themselves (Xue et al., 2007).
Indeed, activation of innate immunity appears to be required for
senescent cells to remove nearby cells. The innate immune
response capacity of macrophages appears to be compromised
with aging (Sebastian et al., 2009), potentially contributing to
senescent cell accumulation in old age.
Cellular senescence and inflammation in obesity
Obesity and serial passage both entail repeated preadipocyte
replication and cellular stress, as well as accumulation of senes-
cent cells, including senescent preadipocytes and endothelial
cells (Minamino et al., 2009; Tchkonia et al., 2009). Adipose
tissue SA b-gal activity and p53 increase with BMI. Abundance
of SA b-gal+ cells also increases in fat tissue in diabetes. Interest-
ingly, p53 and p21 are increased in the fat cell fraction from
subjects with diabetes (Minamino et al., 2009), suggesting a
senescent-like state might occur in differentiated adipocytes,
even though these cells are postmitotic and therefore would not
fit the usual definition of senescence.
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SA b-gal+ cells are more numerous in cultures of preadipo-
cytes and endothelial cells isolated from young obese than lean
rats and humans [Fig. 3; (Tchkonia et al., 2009)]. Extremely
obese subjects can have a burden of over 30-fold more senes-
cent preadipocytes than nonobese subjects (Table 1). These
senescent progenitors in fat tissue might initiate the infiltration
of immune cells that commonly occurs in obesity, a speculation
that merits testing. Immune cells, in turn, could further activate
the preadipocyte population into a pro-inflammatory state.
Consistent with this possibility, coculture of 3T3-L1 preadipo-
cytes with RAW264 macrophages without direct contact
induces a pro-inflammatory state with increased TNFa expres-
sion in the preadipocytes (Suganami et al., 2005). Neutralizing
anti-TNFa antibody prevents this.
A high burden of senescent cells in obesity could have sub-
stantial clinical impact because: (i) senescent cells restricted to a
single tissue can have widespread systemic effects (Keyes et al.,
2006); (ii) many of the pro-inflammatory cytokines and chemo-
kines released by these cells are associated with development of
diabetes and metabolic disease; and (iii) fat is frequently the
largest organ in humans. Consistent with this, upregulating p53
in fat cells and macrophages induces senescence and increases
insulin resistance and inflammatory cytokines in mouse fat (Min-
amino et al., 2009). Conversely, expressing dominant-negative
p53 in fat cells and macrophages confers protection against the
insulin resistance and increased fat tissue cytokines, macro-
phage infiltration, and SA b-gal activity caused by high fat diets
(Minamino et al., 2009). Thus, cellular senescence owing to high
p53 and the resulting pro-inflammatory secretory phenotype
could contribute to morbidity associated with obesity.
Diabetes itself is associated with cellular senescence in fat tis-
sue. Fat tissue from diabetic humans has increased SA b-gal
activity and p53, TNFa, and MCP-1 expression (Minamino et al.,
2009). Other fat tissue disorders, such as lipodystrophy in
patients with human immunodeficiency virus (HIV) infection
treated with certain antiretroviral drugs, cause fat redistribution,
diabetes, and metabolic syndrome. The antiretrovirals stavudine
and zidovudine cause senescence, with SA b-gal positivity,
senescent morphology, and increased p16 and p21, in cultured
human fibroblasts and 3T3-F442A murine preadipocytes (Caron
et al., 2008). Fat tissue from patients with HIV who are on these
drugs can contain senescent cells. Induction of senescence in
3T3-F442A preadipocytes, which are an immortal cell line, indi-
cates these agents can induce preadipocyte senescence inde-
pendently of replicative history. Cyclo-oxygenase-2 decreases in
parallel with induction of senescence by these antiretrovirals,
suggesting an association with oxidative stress. Consistent with
this, exposure of human preadipocytes to H2O2 causes increased
levels of p53, TNFa, and MCP-1 (Minamino et al., 2009).
Fat tissue inflammation and cellular senescence with
aging
As in obesity, aging is frequently associated with increased fat
tissue and circulating pro-inflammatory cytokines, including
TNFa and IL-6 (Morin et al., 1997; Starr et al., 2009). Increased
pro-inflammatory cytokine release by preadipocytes activates
adjacent cells into a pro-inflammatory state: TNFa exposure
increases preadipocyte TNFa mRNA (Mack et al., 2009).
Although TNFa and hypoxia also increase preadipocyte cyto-
kines that promote endothelial cell-monocyte adhesion and
macrophage infiltration (Mack et al., 2009), macrophages do
not appear to be a major source of pro-inflammatory cytokines
with aging in fat tissue (Wu et al., 2007). Capacity of macro-
phages to be activated into a pro-inflammatory state by chemo-
kines and cytokines generally declines with aging (Sebastian
et al., 2009). While macrophages increase in particular fat
depots with aging, these increases are less impressive than in
obesity, and macrophage numbers do not increase at all in some
fat depots with aging (Harris et al., 1999; Jerschow et al.,
2007). This is consistent with the possibility that fat cells and
preadipocytes could be the main sources of the increased fat tis-
sue inflammatory cytokines and chemokines with aging. Prea-
dipocytes from old rats release more TNFa than from young rats,
(A) (B) (C) (D)
Fig. 3 Senescent preadipocytes can accumulate in fat tissue of even young individuals. Freshly isolated, whole perirenal fat tissue isolated from 2-month-old
obese male Zucker rats was assayed for senescence-associated b-galactosidase (A; SA b-gal) or stained with DAPI to show nuclei (B; representative of N = 3
animals). Preadipocytes cultured from young obese rats had senescent-associated heterochromatic foci. Senescent cells are also increased in high fat-fed mice,
express p53 (Minamino et al., 2009), and are less frequent in age-matched ad libitum fed controls. Human preadipocytes from an obese young adult subject were
SA b-gal positive (C; age 21 years.; body mass index [BMI] 50; representative of six obese subjects), while fewer preadipocytes cultured from a lean subject were
senescent (D; age 26 years.; BMI 23; representative of nine lean subjects). Nevertheless, occasional senescent cells were found in preadipocytes cultured from all
nine young, lean subjects.
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with extent of TNFa release by preadipocytes from old animals
being similar to macrophages (Tchkonia et al., 2007a). IL-6
expression is also higher in preadipocytes from old than younger
rats (Cartwright et al., 2010). Preadipocytes from old rats and
the cytokines they produce can impede adipogenesis in nearby
fat cells, potentially contributing to age-related lipodystrophy
and fat redistribution (Tchkonia et al., 2007a; Gustafson et al.,
2009).
Age-related increases in fat tissue inflammatory cytokine and
chemokine expression vary among fat depots (Starr et al., 2009;
Cartwright et al., 2010). Basal IL-6, complement factor 1q, and
MMP3 and MMP12 increase with aging in extraperitoneal but
not intraperitoneal rat preadipocytes (Cartwright et al., 2010).
Increases in IL-6 caused by treatment with LPS are sixfold higher
in visceral (epididymal) and 33-fold higher in interscapular sub-
cutaneous fat from old (27 months) than younger (6 months)
mice (Starr et al., 2009). Thus, the extent of the age-related
increase in IL-6 response is 5- to 10-fold greater in subcutaneous
than visceral fat, suggesting that age-related changes in fat tis-
sue function are more extensive in subcutaneous than visceral
fat. Consistent with this, preadipocyte pro-inflammatory cyto-
kine, chemokine, and ECM modifier production is greater in
extra- than intra-peritoneal fat in old age (Cartwright et al.,
2010). These differences among depots in the trajectory of age-
related preadipocyte dysfunction may contribute to dispropor-
tional loss of subcutaneous fat.
Age-related changes in fat tissue inflammatory profiles resem-
ble those in obesity, in which senescent preadipocytes and
endothelial cells accumulate, as well as the senescent secretory
phenotype reported in skin fibroblasts and other cell types
in vitro [Table 2; (Krtolica & Campisi, 2002; Parrinello et al.,
2005; Xue et al., 2007; Coppe´ et al., 2008; Minamino et al.,
2009; Tchkonia et al., 2009; Cartwright et al., 2010)]. SA b-gal
activity and p16 reactivity are increased in fat tissue of mice with
accelerated aging phenotypes owing to hypomorphism of the
Bubr1 gene (Baker et al., 2006) and after several generations of
telomerase deficiency (Minamino et al., 2009). Importantly,
p16Ink4a ablation prevents accumulation of senescent cells in
BubR1 hypomorphic mice, implicating p16Ink4a in establishing
the senescent phenotype in this model (Baker et al., 2008).
Together, these findings suggest senescent cells could accumu-
late in fat tissue with chronological aging and that these cells
might contribute to age-related fat tissue inflammation and
dysfunction.
Hypothetical model and potential
implications
Cellular senescence could be pivotal in the impact of fat tissue
on systemic metabolism and healthspan. Cellular senescence,
arguably a normally adaptive response to injury or infection,
could instead become a root cause of inflammation, failure to
sequester fatty acids, and dysfunction both in fat tissue and sys-
temically during aging and in obesity (Fig. 1). In fat, extensive
progenitor turnover, high fatty acid levels, toxic metabolites,
prolonged IGF-1 exposure, and other mitogens could initiate
senescence. Senescence might then spread from cell to cell,
involving differentiated fat cells as well as preadipocytes and
endothelial cells. Cytokines and chemokines produced by senes-
cent cells appear to be capable of activating adaptive and innate
immune responses that could spread cellular senescence locally
and systemically. ECM-modifying proteases might expose fat tis-
sue autoantigens or generate neoantigens, further exacerbating
the process. Failure to remove senescent cells may contribute to
their accumulation, both because of age-related macrophage
dysfunction and effects of ECM-modifying proteases on recep-
tors and other proteins required for optimal immune clearance.
If this hypothetical model is valid, senescent cells and their prod-
ucts would be a logical target for therapeutic intervention in
age- and obesity-related metabolic disease.
This speculative model and recent findings about fat tissue
cellular senescence and inflammation prompt several questions
about cellular senescence (Table S1). Among these are the fol-
lowing: (i) Is cellular senescence effectively an alternative form
of differentiation? (ii) Can a senescent-like state develop in ter-
minally differentiated cells? (iii) Can senescence occur at any
stage during life? (iv) Does senescence spread from cell to cell in
fat tissue in vivo? (v) Does failure of the immune system to
remove senescent cells contribute to their accumulation in old
age? and (vi) Is cellular senescence really at the root of age- and
obesity-related fat tissue inflammation and metabolic dysfunc-
tion? As discussed later, suggestive evidence supports affirma-
tive answers to some of these questions, but more work is
required to address them definitively.
Is cellular senescence effectively an alternative form of differ-
entiation? Cellular senescence can be viewed as a response to
Table 2 Parallels among preadipocyte and fat tissue changes in obesity,
chronological aging, and after repeated replication of cultured preadipocytes
and fibroblasts
Property Obesity
Repeated
replication Aging
Dysdifferentiation  * 
› Inflammation   
› TNFa, IL6, MMPs, PAI-1  † 
Altered progenitor shape   
Insulin resistance  
› Senescence associated b-gal §  
ﬂ b oxidation, PGC-1a – 
› Stathmin-like-2 (Stmn-2)  
Cell dynamic and molecular mechanisms underlying fat tissue dysfunction
in obesity in younger individuals are strikingly similar to aging. Similarities
between changes in human preadipocyte and fibroblast function after
serial passage in vitro to those in preadipocytes from obese or old subjects
further support this (Tchkonia et al., 2006b, 2009). Thus, obesity, in some
respects, resembles an accelerated form of fat tissue aging, potentially
involving fat cell progenitor hyperplasia and cellular stress.
*In (Tchkonia et al., 2006b; Noer et al., 2009).
†In (Mu & Higgins, 1995).
(Cartwright et al., 2010).
§In (Minamino et al., 2009; Tchkonia et al., 2009).
–In (Semple et al., 2004). Other references appear in the text.
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cellular stress (Ben-Porath & Weinberg, 2004). In preadipocytes,
cellular senescence, the age-associated MAD state, the pro-
inflammatory secretory state activated by cytokines, LPS, fatty
acids, ROS, ceramide, cellular stress pathways, or other signals,
and the macrophage-like phenotype that preadipocytes can
assume may all be related. In addition to preadipocytes, other
types of progenitors appear to be able to assume a state very
much like M1 activated macrophages, based on their gene
expression profiles (Charriere et al., 2006). Acquisition of this
pro-inflammatory state appears to involve extra- and intracellu-
lar signals that integrate to activate: (i) a chain of signaling
molecules; (ii) an orchestrated cascade of transcription factors;
(iii) banks of pro-inflammatory cytokines, chemokines, and
ECM-modifying proteases; (iv) mechanisms that shut down rep-
lication; and (v) mechanisms that prevent usual differentiation.
Perhaps senescence is an alternative cell fate that has much in
common with pro-inflammatory stress-activated states.
Can a senescent-like state develop in terminally differentiated
cells? Terminally differentiated fat cells might be able to acquire
a senescent-like state in both aging and obesity (Wu et al.,
2007; Minamino et al., 2009). Perhaps the view that a cellular
senescent-like state can only occur in dividing cells needs
reconsideration.
Can senescence occur at any stage during life? If our hypo-
thetical model is correct, cellular senescence should be inducible
at any phase in life. Even at early passage, some cells in cultured
human skin fibroblast strains express markers of senescence
(Martin-Ruiz et al., 2004). The proportion of these cells increases
with passaging or following imposition of cellular stress at early
passage (Passos et al., 2007). With respect to fat, senescent cells
can be found in fat tissue and preadipocytes from juvenile ani-
mals and young adult humans with obesity (Fig. 3). The answer
to this question appears to be yes.
Does cellular senescence spread from cell to cell? Cultured
human cells and mouse cells in vivo that have DNA double-
strand breaks and cH2AX induced by radiation can induce DNA
damage responses and cH2AX foci in nearby cells (Sokolov
et al., 2007). Cytokines secreted by activated preadipocytes,
macrophages, and endothelial cells can induce chemokine and
cytokine expression in bystander cells in a pattern like that of the
senescent secretory phenotype (Suganami et al., 2005; Mack
et al., 2009). TNFa induces cellular senescence in preadipocytes,
endothelial progenitor cells, and skin fibroblasts (Keyes et al.,
2006; Tchkonia et al., 2009; Zhang et al., 2009). Thus, it seems
senescence can spread locally from cell to cell. It will be interest-
ing to test whether fat tissue cellular senescence induced by
obesity leads to generation of senescent cells elsewhere, such as
in the brain. Indeed, high fat feeding induces cellular senescence
in aortic endothelium, a process that is mediated by Akt and
mTOR and inhibited by rapamycin (Wang et al., 2009b).
Whether aortic endothelial senescence results directly from
increased circulating lipids owing to the high fat diet, hormones
affected by the diet (e.g., insulin or IGF-1), cytokines released by
senescent cells in fat or elsewhere, or a combination of mecha-
nisms remains to be determined.
Does failure of the immune system to remove senescent cells
contribute to their accumulation in old age? Macrophage func-
tion generally declines with aging (Sebastian et al., 2009). Age-
related alterations in the stromal microenvironment, including
cytokine imbalance, could further impede macrophage function
(Stout & Suttles, 2005), possibly augmenting senescent cell
accumulation. This question needs to be addressed specifically
in fat tissue macrophages, because macrophage properties are
highly tissue dependent (Stout & Suttles, 2005; Sebastian et al.,
2009).
Is cellular senescence at the root of age- and obesity-related
fat tissue inflammation and metabolic dysfunction? The poten-
tially central role of preadipocytes in genesis of fat tissue inflam-
mation and metabolic dysfunction has not received much
attention. Preadipocyte cellular stress can result from repeated
replication, hypoxia, ROS, chronic effects of free fatty acids or
other lipids such as ceramide, hyperglycemia, or other metabolic
signals. These appear to activate innate immune responses in
preadipocytes, causing further cytokine and chemokine genera-
tion, potentially inducing spread of activation of pro-inflamma-
tory responses to nearby preadipocytes and other cell types and
attraction of immune cells. The preadipocyte pro-inflammatory
phenotype might impede protection against lipotoxicity, con-
tributing to systemic consequences in aging similar to those in
lipodystrophies and obesity. The pathways and processes culmi-
nating in this generation of activated or senescent preadipocytes
and fat cells represent potential new targets for intervention.
It seems a senescent-like, pro-inflammatory fate can be
acquired in response to intra- or extracellular danger signals,
inflammation, infection, excessive replication, or toxic metabo-
lites. This spectrum of cell fates may prevent differentiation
along pathways that are not desirable in the context of damage.
In the case of fat tissue, this could involve preventing develop-
ment of new fat cells or enlargement of existing ones in favor of
acquiring cells capable of facilitating repair. Perhaps terminally
differentiated cells are able to enter a senescent secretory state
related to the molecular pathways that initiate senescence in
dividing cell types. Studies in fat tissue are beginning to suggest
that cellular senescence could be an alternative cell fate involv-
ing activation of pro-inflammatory responses owing to intra- or
extracellular injury signals at any stage of life.
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